Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global generic drugs market size reached a value of almost USD 370 billion in the year 2020. The market is further expected to grow at a CAGR of 5.5% between 2021 and 2026 to reach a value of almost USD 510.2 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global generic drugs market is driven by the rising cardiometabolic risk factors across the globe. The United States is the leading regional market. This can be attributed to the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the manufacturing of these drugs, further aiding the market growth in the region.
Generic drugs are referred to as the bioequivalent of brand-name drugs on the basis of safety, strength, quality, stability, impact, intended use, dosage form, and the route of administration. These drugs are established to be safe and effective just as their already marketed brand-name formulation. Generic drug manufacturers are not required to invest in drug research or drug development and marketing, which makes these medicines cost-effective, thereby contributing to their widespread preference.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The generic drugs market is segmented on the basis of application into:
Among all of these, cardiovascular diseases represent the largest segment in the market.
On the basis of drug delivery, the industry is divided into:
Oral generic drugs at present account for a majority of the total market share.
On the basis of distribution channel, the industry is bifurcated into:
Out of these, retail pharmacies represent a clear dominance in the global generic drugs market.
The report also covers the regional markets like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global generic drugs market is driven by the significant rise in the cardiometabolic risk factors among the population. In addition to this, due to various factors, such as changing dietary patterns, sedentary lifestyles, and hectic working schedules, there is a growing prevalence of diabetes, dyslipidaemia, hypertension, metabolic syndrome, and obesity. This has resulted in a considerable rise in the uptake of medicines, thereby accelerating the growth of the industry.
The global generic drugs market is further enhanced by the huge costs related to the medication of various chronic and lifestyle diseases, which have led to the increase in the consumer inclination toward affordable variants, further boosting the demand. Apart from this, the patent expiration of crucial blockbuster drugs, in conjunction with multiple favourable initiatives undertaken by the governments of several countries to promote the usage of generic drugs, is anticipated to propel the industry growth. Numerous regulatory bodies are implementing rigorous reviews to ensure optimum standards during the manufacturing of these drugs.
The report gives a detailed analysis of the following key players in the global generic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2020 |
Historical Period | 2017-2021 |
Forecast Period | 2022-2027 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Application, Drug Delivery, Distribution Channel, Region |
Breakup by Application | CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, Others |
Breakup by Drug Delivery | Oral, Injectables, Dermal/Topical, Inhalers |
Breakup by Distribution Channel | Retail Pharmacies, Hospital Pharmacies |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Generic Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Generic Drugs Historical Market (2017-2021)
8.3 Global Generic Drugs Market Forecast (2022-2027)
8.4 Global Generic Drugs Market by Application
8.4.1 CNS
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Cardiovascular
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Dermatology
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Genitourinary/Hormonal
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Respiratory
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2017-2021)
8.4.5.3 Forecast Trend (2022-2027)
8.4.6 Rheumatology
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2017-2021)
8.4.6.3 Forecast Trend (2022-2027)
8.4.7 Diabetes
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2017-2021)
8.4.7.3 Forecast Trend (2022-2027)
8.4.8 Oncology
8.4.8.1 Market Share
8.4.8.2 Historical Trend (2017-2021)
8.4.8.3 Forecast Trend (2022-2027)
8.4.9 Others
8.5 Global Generic Drugs Market by Drug Delivery
8.5.1 Oral
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Injectables
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Dermal/Topical
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Inhalers
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.6 Global Generic Drugs Market by Distribution Channel
8.6.1 Retail Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Hospital Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.7 Global Generic Drugs Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Project Economics
12.1 Capital Cost of the Project
12.2 Techno-Economic Parameters
12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
12.4 Taxation and Depreciation
12.5 Income Projections
12.6 Expenditure Projections
12.7 Financial Analysis
12.8 Profit Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Company Profiles
13.3.1 Teva Pharmaceutical Industries Ltd.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Demographic Reach and Achievements
13.3.1.4 Certifications
13.3.2 Mylan N.V.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Demographic Reach and Achievements
13.3.2.4 Certifications
13.3.3 Novartis AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Demographic Reach and Achievements
13.3.3.4 Certifications
13.3.4 Sun Pharmaceutical Industries Ltd.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Demographic Reach and Achievements
13.3.4.4 Certifications
13.3.5 Fresenius Kabi AG
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Demographic Reach and Achievements
13.3.5.4 Certifications
13.3.6 Others
14 Industry Events and Developments
List of Key Figures and Tables
1. Global Generic Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Generic Drugs Historical Market: Breakup by Application (USD Billion), 2017-2021
3. Global Generic Drugs Market Forecast: Breakup by Application (USD Billion), 2022-2027
4. Global Generic Drugs Historical Market: Breakup by Drug Delivery (USD Billion), 2017-2021
5. Global Generic Drugs Market Forecast: Breakup by Drug Delivery (USD Billion), 2022-2027
6. Global Generic Drugs Historical Market: Breakup by Distribution Channel (USD Billion), 2017-2021
7. Global Generic Drugs Market Forecast: Breakup by Distribution Channel (USD Billion), 2022-2027
8. Global Generic Drugs Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Generic Drugs Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Generic Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Generic Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Generic Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Generic Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Generic Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Generic Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Generic Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Generic Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Generic Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Generic Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Generic Drugs Market Structure
The global generic drugs market reached a value of USD 370 billion in 2020.
The industry is projected to grow at a CAGR of nearly 5.5% in the forecast period of 2022-2027.
The industry is estimated to reach a value of about USD 510.2 billion by 2026.
The major drivers of the industry include rising disposable incomes, increasing population, rising cardiometabolic risk factors, and the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the production of these drugs.
Various favourable initiatives undertaken by the governments of multiple countries is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
Cardiovascular disease is the dominant application segment in the industry.
Oral generic drugs are the leading delivery type of the product in the industry.
The retail pharmacies account for the largest market share, among other distribution channels in the industry.
The leading players in the industry are Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., and Fresenius Kabi AG, among others.
The global generic drugs market attained a value of USD 370 billion in 2020, driven by the rising cardiometabolic risk factors. Aided by the favourable initiatives undertaken by the governments, the industry is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 5.5%. The industry is projected to reach USD 510.2 billion by 2026.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on its applications, the market can be segmented into CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology, among others, with cardiovascular accounting for the largest market share. By drug delivery, the industry is led by oral generic drugs. On the basis of distribution channels, the global industry is led by retail pharmacies. The major regional markets are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., and Fresenius Kabi AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.